Tenofovir-based Prophylaxis
Tenofovir-Based Prophylaxis is a pharmacological intervention within the class of antiretroviral pre-exposure and post-exposure prophylactic regimens that employs tenofovir, a nucleotide reverse transcriptase inhibitor, as a foundational agent to prevent HIV acquisition through systemic suppression of viral replication in exposed individuals.
306
Publications
23.2K
Citations
2.3K
Authors
709
Institutions
Publications per year
2017–2026
155
Parents
306
1–5 of 306
2.3K
University of Colorado Anschutz Medical Campus, United States
38 publications · 3.4K citations
24
h-index
23
h-index
21
h-index
21
h-index
18
h-index
1–5 of 2.3K
709
University of California, San Francisco
San Francisco, United States
31 h-index
158 publications
18.8K citations

Centers for Disease Control and Prevention
Atlanta, United States
26 h-index
212 publications
12.9K citations

Johns Hopkins University
Baltimore, United States
26 h-index
134 publications
12.2K citations
University of Washington
Seattle, United States
25 h-index
166 publications
17.3K citations
Gilead Sciences (United States)
Foster City, United States
24 h-index
77 publications
9.9K citations
Harvard University
Cambridge, United States
23 h-index
72 publications
12.4K citations
Fred Hutch Cancer Center
Seattle, United States
20 h-index
73 publications
7.1K citations

Johns Hopkins Medicine
Baltimore, United States
20 h-index
73 publications
3.6K citations
1–8 of 709
35 publications · 2.1K citations
24
h-index
CID · 27 publications · 1.6K citations
20
h-index
25 publications · 1.5K citations
19
h-index
JID · 21 publications · 1.2K citations
18
h-index
19 publications · 1.1K citations
17
h-index
1–5